Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB122 (Oral Edaravone) in ALS (ADOREXT)
NCT05866926Phase 3Terminated
- Sponsor
- Ferrer
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of FAB122 in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Ferrer. Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events at 44 weeks. Started Mar 2023; status: terminated.
02
Drugs
FAB122
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05866926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866926.